NZ580413A - The use of pde7 inhibitors for the treatment of movement disorders - Google Patents
The use of pde7 inhibitors for the treatment of movement disordersInfo
- Publication number
- NZ580413A NZ580413A NZ580413A NZ58041308A NZ580413A NZ 580413 A NZ580413 A NZ 580413A NZ 580413 A NZ580413 A NZ 580413A NZ 58041308 A NZ58041308 A NZ 58041308A NZ 580413 A NZ580413 A NZ 580413A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pde7
- treatment
- movement
- neurological
- movement disorders
- Prior art date
Links
- 208000016285 Movement disease Diseases 0.000 title abstract 4
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 title abstract 2
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 title abstract 2
- 101100407335 Dictyostelium discoideum pde7 gene Proteins 0.000 abstract 4
- 230000005856 abnormality Effects 0.000 abstract 3
- 230000000926 neurological effect Effects 0.000 abstract 3
- 229940098778 Dopamine receptor agonist Drugs 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 abstract 2
- 230000002255 enzymatic effect Effects 0.000 abstract 2
- 230000007170 pathology Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92049607P | 2007-03-27 | 2007-03-27 | |
PCT/US2008/058530 WO2008119057A2 (en) | 2007-03-27 | 2008-03-27 | The use of pde7 inhibitors for the treatment of movement disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ580413A true NZ580413A (en) | 2012-11-30 |
Family
ID=39789284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ580413A NZ580413A (en) | 2007-03-27 | 2008-03-27 | The use of pde7 inhibitors for the treatment of movement disorders |
Country Status (13)
Country | Link |
---|---|
US (3) | US20080260643A1 (es) |
EP (1) | EP2139475B1 (es) |
JP (2) | JP5580192B2 (es) |
CN (2) | CN101917992A (es) |
AU (1) | AU2008230710B2 (es) |
BR (1) | BRPI0809244A2 (es) |
CA (1) | CA2681650C (es) |
ES (1) | ES2533206T3 (es) |
HK (1) | HK1139861A1 (es) |
MX (1) | MX2009010450A (es) |
NZ (1) | NZ580413A (es) |
RU (1) | RU2449790C2 (es) |
WO (1) | WO2008119057A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
CA2755768A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
FR2943673B1 (fr) | 2009-03-27 | 2013-03-29 | Sanofi Aventis | Applications therapeutiques de derives de quinazolinedione |
FR2944206B1 (fr) | 2009-04-09 | 2012-12-28 | Sanofi Aventis | Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione |
FR2944282B1 (fr) | 2009-04-09 | 2013-05-03 | Sanofi Aventis | Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques |
AU2013202493B2 (en) * | 2009-05-04 | 2016-03-10 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
ES2353093B1 (es) * | 2009-05-20 | 2012-01-03 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas. |
ES2360783B1 (es) | 2009-10-02 | 2012-07-04 | Consejo Superior De Investigaciones Científicas (Csic) | 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas |
CN103547267A (zh) * | 2010-11-08 | 2014-01-29 | 奥默罗斯公司 | 使用pde7抑制剂治疗成瘾和冲动控制障碍 |
US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
DK2846805T3 (en) * | 2012-05-07 | 2019-03-18 | Omeros Corp | TREATMENT OF DEPENDENCE AND IMPULSE CONTROL DISORDERS USING PDE7 INHIBITORS |
CN112168972A (zh) * | 2012-05-07 | 2021-01-05 | 奥默罗斯公司 | 使用pde7抑制剂治疗成瘾和冲动控制障碍 |
MX2019002281A (es) * | 2016-08-26 | 2019-06-20 | Mitsubishi Tanabe Pharma Corp | Compuesto heterociclico nitrogenado biciclico. |
WO2020050722A1 (en) * | 2018-09-05 | 2020-03-12 | Universiteit Van Amsterdam | Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease |
WO2024038090A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
RO114469B1 (ro) | 1987-12-15 | 1999-04-30 | Gene Shears Pty Ltd | Compus oligoribonucleotidic, procedeu de preparare si metoda de inactivare |
GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
US5932465A (en) * | 1997-10-16 | 1999-08-03 | Icos Corporation | Phosphodiesterase 8A |
WO1999042596A2 (en) * | 1998-02-23 | 1999-08-26 | Icos Corporation | Phosphodiesterase 10 |
EP1018559B8 (en) * | 1998-12-23 | 2007-11-28 | Pfizer Limited | Phosphodiesterase enzymes |
AU4589800A (en) | 1999-05-05 | 2000-11-21 | Darwin Discovery Limited | 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors |
CA2373073A1 (en) | 1999-05-07 | 2000-11-16 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
US6146876A (en) | 1999-06-11 | 2000-11-14 | Millennium Pharmaceuticals, Inc. | 22025, a novel human cyclic nucleotide phosphodiesterase |
DE19950647A1 (de) | 1999-10-21 | 2001-04-26 | Merck Patent Gmbh | Imidazolderivate als Phosphodiesterase VII-Hemmer |
US7491742B2 (en) * | 1999-10-21 | 2009-02-17 | Merck Patent Gmbh | Imidazole derivatives as phosphodiesterase VII inhibitors |
DE19953024A1 (de) * | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Isoxazolderivate als Phosphodiesterase VII-Hemmer |
DE19953025A1 (de) | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Pyrrolderivate als Phosphodiesterase VII-Hemmer |
DE19953414A1 (de) * | 1999-11-06 | 2001-05-10 | Merck Patent Gmbh | Imidazopyridinderivate als Phospodiesterase VII-Hemmer |
DE19954707A1 (de) * | 1999-11-13 | 2001-05-17 | Merck Patent Gmbh | Imidazolverbindungen als Phosphodiesterase VII-Hemmer |
US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
WO2001062290A2 (en) * | 2000-02-22 | 2001-08-30 | Cellegy Canada Inc. | Methods and compositions for improving sleep |
WO2001062904A1 (en) | 2000-02-24 | 2001-08-30 | Bayer Aktiengesellschaft | Regulation of human gelatinase b-like enzyme 1 |
GB0007934D0 (en) | 2000-03-31 | 2000-05-17 | Darwin Discovery Ltd | Chemical compounds |
US7345031B2 (en) * | 2000-04-12 | 2008-03-18 | International Medical Innovations, Inc. | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use |
GB0015095D0 (en) | 2000-06-20 | 2000-08-09 | Celltech Chiroscience Ltd | Chemical compounds |
CA2419623A1 (en) | 2000-08-30 | 2002-03-07 | Lilly Icos Llc | Method for treatment of migraine using pde5 inhibitors |
EP1193261A1 (en) * | 2000-10-02 | 2002-04-03 | Warner-Lambert Company | New thiadiazoles and their use as phosphodiesterase-7 inhibitors |
AU2002224835A1 (en) | 2000-11-14 | 2002-05-27 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Dihydroisoquinolines as novel phosphodiesterase inhibitors |
NZ525147A (en) | 2000-11-14 | 2004-10-29 | Altana Pharma Ag | (Dihydro)isoquinoline derivatives as phosphodiesterase inhibitors |
IL140844A0 (en) * | 2001-01-10 | 2002-02-10 | Polygene Ltd | Cationic polysaccharide compositions |
CA2439691A1 (en) * | 2001-03-02 | 2002-09-12 | Bristol-Myers Squibb Company | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
US6617357B2 (en) | 2001-03-06 | 2003-09-09 | Smithkline Beecham Corporation | Compounds and their use as PDE inhibitors |
AP1699A (en) * | 2001-03-21 | 2006-12-26 | Warner Lambert Co | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
EP1385843A1 (en) | 2001-04-18 | 2004-02-04 | Ortho-Mcneil Pharmaceutical, Inc. | Arylindenopyridines with pde inhibiting activity |
US6903109B2 (en) * | 2001-04-18 | 2005-06-07 | Ortho-Muniel Pharmaceutical, Inc. | Arylindenopyridines and related therapeutic and prophylactic methods |
US6958328B2 (en) | 2001-04-18 | 2005-10-25 | Ortho-Mcneil Pharmaceutical, Inc | Arylindenopyridines and related therapeutic and prophylactic methods |
US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
MXPA03009583A (es) | 2001-04-25 | 2004-02-12 | Altana Pharma Ag | Ftalazinonas novedosas. |
MXPA03009925A (es) | 2001-04-30 | 2004-06-30 | Bayer Pharmaceuticals Corp | Nuevas tiofeno [2,3-d]pirimidinas 4-amino-5,6-sustituidas. |
US20030053980A1 (en) | 2001-04-30 | 2003-03-20 | The Gillette Company | Shaving compositions containing highly lubricious water soluble polymers |
WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
US7196080B2 (en) * | 2001-06-15 | 2007-03-27 | Astellas Pharma Inc. | Phenylpyridinecarbonylpiperazinederivative |
PE20030008A1 (es) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
JP2005500294A (ja) * | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ7に対するピリミジン阻害剤 |
DE10130167A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
JP2005511500A (ja) * | 2001-08-31 | 2005-04-28 | ザ ロックフェラー ユニバーシティー | 脳におけるホスホジエステラーゼ活性およびホスホジエステラーゼ1b媒介シグナル伝達の調節 |
US20060286622A1 (en) * | 2001-09-28 | 2006-12-21 | Patricia Soulard | Polypeptides exhibiting PDE7 activity and their use for selecting compounds which inhibit PDE 7 enzyme activity |
DE60222931T2 (de) * | 2001-12-13 | 2008-07-10 | Asubio Pharma Co., Ltd. | Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung |
DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
AU2002360774A1 (en) | 2001-12-28 | 2003-07-24 | Bayer Corporation | 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones |
WO2003064389A1 (fr) * | 2002-01-31 | 2003-08-07 | Ono Pharmaceutical Co., Ltd. | Composes bicycliques contenant de l'azote et medicaments contenant ces composes en tant qu'ingredient actif |
US20040082061A1 (en) * | 2002-02-14 | 2004-04-29 | Anna Astromoff | Drug metabolizing enzymes |
EP1348433A1 (en) | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | Thiazol-2-yl-imine compounds as PDE-7 inhibitors |
EP1348701A1 (en) | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors |
EP1400244A1 (en) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
EP1608742A1 (en) | 2002-11-13 | 2005-12-28 | Bayer HealthCare AG | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7B (PDE7b) |
ES2217956B1 (es) | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
US7217527B2 (en) * | 2003-04-15 | 2007-05-15 | Vanderbilt University | Assay for phosphodiesterase function |
JP2006219374A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するイミダゾトリアジノン誘導体 |
JP2006219373A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
WO2005018563A2 (en) * | 2003-08-22 | 2005-03-03 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury |
CN1976938B (zh) | 2004-07-01 | 2012-08-15 | 第一三共株式会社 | 具有pde7抑制活性的噻吩并吡唑衍生物 |
RU2007132865A (ru) | 2005-03-01 | 2009-03-10 | Пфайзер Лимитед (GB) | Применение ингибиторов pde7 для лечения невропатической боли |
WO2006092692A1 (en) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
AU2006304787A1 (en) * | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
MEP0408A (xx) * | 2005-12-02 | 2010-02-10 | Pfizer Ltd | Derivati hinociklicnog hinazolina kao inhibitori pde7 |
US8637528B2 (en) * | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
-
2008
- 2008-03-27 ES ES08744515.1T patent/ES2533206T3/es active Active
- 2008-03-27 AU AU2008230710A patent/AU2008230710B2/en active Active
- 2008-03-27 NZ NZ580413A patent/NZ580413A/xx unknown
- 2008-03-27 WO PCT/US2008/058530 patent/WO2008119057A2/en active Application Filing
- 2008-03-27 CA CA2681650A patent/CA2681650C/en active Active
- 2008-03-27 CN CN200880017058XA patent/CN101917992A/zh active Pending
- 2008-03-27 MX MX2009010450A patent/MX2009010450A/es active IP Right Grant
- 2008-03-27 CN CN201510082785.6A patent/CN104758291B/zh active Active
- 2008-03-27 RU RU2009138966/15A patent/RU2449790C2/ru active
- 2008-03-27 EP EP08744515.1A patent/EP2139475B1/en active Active
- 2008-03-27 JP JP2010501232A patent/JP5580192B2/ja active Active
- 2008-03-27 BR BRPI0809244-3A patent/BRPI0809244A2/pt not_active Application Discontinuation
- 2008-03-27 US US12/057,368 patent/US20080260643A1/en not_active Abandoned
-
2010
- 2010-07-05 HK HK10106488.4A patent/HK1139861A1/xx unknown
- 2010-12-21 US US12/974,693 patent/US20110091388A1/en not_active Abandoned
-
2014
- 2014-05-28 JP JP2014109910A patent/JP5943964B2/ja active Active
-
2018
- 2018-12-06 US US16/212,064 patent/US20190183824A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2139475A4 (en) | 2012-03-07 |
AU2008230710A1 (en) | 2008-10-02 |
US20110091388A1 (en) | 2011-04-21 |
JP2014198718A (ja) | 2014-10-23 |
EP2139475A2 (en) | 2010-01-06 |
JP2010522768A (ja) | 2010-07-08 |
CN104758291A (zh) | 2015-07-08 |
CN104758291B (zh) | 2020-03-03 |
ES2533206T3 (es) | 2015-04-08 |
EP2139475B1 (en) | 2014-12-17 |
RU2009138966A (ru) | 2011-05-10 |
WO2008119057A2 (en) | 2008-10-02 |
MX2009010450A (es) | 2009-11-23 |
RU2449790C2 (ru) | 2012-05-10 |
CN101917992A (zh) | 2010-12-15 |
AU2008230710B2 (en) | 2014-04-10 |
CA2681650A1 (en) | 2008-10-02 |
HK1139861A1 (en) | 2010-09-30 |
JP5580192B2 (ja) | 2014-08-27 |
CA2681650C (en) | 2016-11-22 |
WO2008119057A3 (en) | 2008-11-20 |
US20190183824A1 (en) | 2019-06-20 |
BRPI0809244A2 (pt) | 2014-09-23 |
US20080260643A1 (en) | 2008-10-23 |
JP5943964B2 (ja) | 2016-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ580413A (en) | The use of pde7 inhibitors for the treatment of movement disorders | |
NZ628054A (en) | Treatment of addiction and impulse-control disorders using pde7 inhibitors | |
MX2010005343A (es) | Compuestos indola 3, 5-sustituidos que tienen actividad inhibidora de la re-absorcion y el reciclo de nos y norepinefrina. | |
EA201290041A1 (ru) | Лечение расстройств, связанных с макрофагами | |
MX366774B (es) | Uso de oligonucleótidos antisentido en la inhibición de transcrito antisentido natural para sirtuina 1. | |
MX2011011656A (es) | Uso de los inhibidores de la fosfodiesterasa 7 para el tratamiento de trastornos del movimiento. | |
UA96777C2 (ru) | Фенилпропионамидные соединения и их применение как опиоидных агонистов | |
MX2009009304A (es) | Inhibidores de cinasa pim y metodos para su uso. | |
TN2009000224A1 (en) | Inhibitors of akt activity | |
MX2012000817A (es) | Tratamiento para desordenes del higado con inhibidores pi3k. | |
WO2008022024A3 (en) | Imidazole amines as inhibitors of beta-secretase | |
MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
HK1141231A1 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of migraine | |
NZ710443A (en) | Method of identifying disease risk factors | |
MY156243A (en) | Treatment for diabetes in patients inappropriate for metformin therapy | |
WO2007085019A3 (en) | Methods of treating or preventing sinusitis with oxidative reductive potential water solution | |
MX2012000034A (es) | Metodos para el tratamiento o la prevencion de la fatiga. | |
BR112012021905A2 (pt) | tratamento de nefrite lúpica usando laquinimod | |
TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
NZ595252A (en) | Biofilm treatment | |
IN2012DN02782A (es) | ||
NZ706740A (en) | Use of vap-1 inhibitors for treating fibrotic conditions | |
WO2008155390A3 (en) | Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases. | |
HK1129275A1 (en) | Treatment of inflammatory disorders with triazole compounds | |
WO2009131850A3 (en) | Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 MAR 2015 BY CPA GLOBAL Effective date: 20130517 |
|
ERR | Error or correction |
Free format text: THE OWNER HAS BEEN CORRECTED TO 3103871, OMEROS CORPORATION, 201 ELLIOTT AVENUE WEST, SEATTLE, WASHINGTON 98119, US Effective date: 20140403 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAR 2016 BY CPA GLOBAL Effective date: 20150217 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAR 2017 BY COMPUTER PACKAGES INC Effective date: 20160301 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAR 2018 BY COMPUTER PACKAGES INC Effective date: 20170302 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAR 2019 BY COMPUTER PACKAGES INC Effective date: 20180302 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAR 2020 BY COMPUTER PACKAGES INC Effective date: 20190302 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAR 2021 BY COMPUTER PACKAGES INC Effective date: 20200303 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAR 2022 BY COMPUTER PACKAGES INC Effective date: 20210306 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAR 2023 BY COMPUTER PACKAGES INC Effective date: 20220301 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAR 2024 BY COMPUTER PACKAGES INC Effective date: 20230301 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAR 2025 BY COMPUTER PACKAGES INC Effective date: 20240229 |